Literature DB >> 15520182

Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo.

Melissa M Fraser1, Xiaoyan Zhu, Chang-Hyuk Kwon, Erik J Uhlmann, David H Gutmann, Suzanne J Baker.   

Abstract

Somatic mutations of PTEN are found in many types of cancers including glioblastoma, the most malignant astrocytic tumor. PTEN mutation occurs in 25 to 40% of glioblastomas but is rarely observed in low-grade glial neoplasms. To determine the role of Pten in astrocytes and glial tumor formation, we inactivated Pten by a Cre-loxP approach with a GFAP-cre transgenic mouse that induced Cre-mediated recombination in astrocytes. Pten conditional knockout mice showed a striking progressive enlargement of the entire brain. Increased nuclear and soma size was observed in both astrocytes and neurons, which contributed in part to the increase in brain size. Pten-deficient astrocytes showed accelerated proliferation in vitro and aberrant ongoing proliferation in adult brains in vivo. In contrast, neurons lacking Pten did not show alterations in proliferation. This study shows cell-type dependent effects of Pten loss in the adult brain, including increased astrocyte proliferation that may render astroglial cells susceptible to neoplastic transformation or malignant progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520182     DOI: 10.1158/0008-5472.CAN-04-2487

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  108 in total

1.  Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration.

Authors:  Margaret Sperow; Raymond B Berry; Ildar T Bayazitov; Guo Zhu; Suzanne J Baker; Stanislav S Zakharenko
Journal:  J Physiol       Date:  2011-12-06       Impact factor: 5.182

2.  FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes.

Authors:  Bingbing Dai; Russell O Pieper; Dawei Li; Ping Wei; Mingguang Liu; Shiao Y Woo; Kenneth D Aldape; Raymond Sawaya; Keping Xie; Suyun Huang
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

3.  Tracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling.

Authors:  Fuyi Chen; Joel Rosiene; Alicia Che; Albert Becker; Joseph LoTurco
Journal:  Development       Date:  2015-09-23       Impact factor: 6.868

4.  The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord.

Authors:  Simone Codeluppi; Camilla I Svensson; Michael P Hefferan; Fatima Valencia; Morgan D Silldorff; Masakatsu Oshiro; Martin Marsala; Elena B Pasquale
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

5.  PTEN inhibitor bisperoxovanadium protects oligodendrocytes and myelin and prevents neuronal atrophy in adult rats following cervical hemicontusive spinal cord injury.

Authors:  Chandler L Walker; Xiao-Ming Xu
Journal:  Neurosci Lett       Date:  2014-02-26       Impact factor: 3.046

6.  EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.

Authors:  Enrique C Torchia; Kelli Boyd; Jerold E Rehg; Chunxu Qu; Suzanne J Baker
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

Review 7.  Balancing Proliferation and Connectivity in PTEN-associated Autism Spectrum Disorder.

Authors:  Amanda K Tilot; Thomas W Frazier; Charis Eng
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

Review 8.  Mouse models of DNA double-strand break repair and neurological disease.

Authors:  Pierre-Olivier Frappart; Peter J McKinnon
Journal:  DNA Repair (Amst)       Date:  2008-05-23

9.  Pten haploinsufficiency accelerates formation of high-grade astrocytomas.

Authors:  Chang-Hyuk Kwon; Dawen Zhao; Jian Chen; Sheila Alcantara; Yanjiao Li; Dennis K Burns; Ralph P Mason; Eva Y-H P Lee; Hong Wu; Luis F Parada
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

10.  Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.

Authors:  Alberto Broniscer; Suzanne J Baker; Clinton F Stewart; Thomas E Merchant; Fred H Laningham; Paula Schaiquevich; Mehmet Kocak; E Brannon Morris; Raelene Endersby; David W Ellison; Amar Gajjar
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.